WELIREG, Merck's oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, has been recommended as monotherapy for the treatment of adult patients with certain types of Von Hippel-Lindau or VHL ...
The drug is an antineoplastic agent that acts by blocking the activity of hypoxia-inducible factor 2 alpha (HIF-2α), which regulates cellular proliferation, angiogenesis, and tumor growth. By ...